Canopy Growth Faces Fresh Scrutiny Over Two Year Accounting Error

When a cannabis company finds a two-year accounting mistake inside its own year-end audit process, Wall Street doesn’t exactly shrug and move on. It reacts first and asks questions later. That’s exactly what happened when Canopy Growth dropped a late-Friday disclosure saying it would restate financial results for fiscal 2024 and 2025 after uncovering a financial reporting error tied to foreign-currency-denominated warrants. By Tuesday, investors had already hit the panic button. Shares slid nearly 6%, extending a brutal stretch that has already seen the stock fall 14% year-to-date and roughly 41% over the last 12 months. And while Canopy insists the issue is “non-cash” and doesn’t affect core operations, the episode shines a bright spotlight on something finance professionals know all too well: technical accounting errors can still create very real credibility problems.

Somebody Put the Warrants in the Wrong Bucket?

At the center of the issue is a classic accounting classification mistake involving share-settled warrants. Canopy Growth, whose functional currency is the Canadian dollar, issued warrants with exercise prices denominated in U.S. dollars during fiscal 2024. Under IFRS accounting standards, specifically IAS 32 and IFRS 9, that matters a lot more than it sounds. Because the exercise price was tied to a foreign currency, the warrants failed the “fixed-for-fixed” equity classification test. Instead of being treated as equity instruments, they should have been classified as financial liabilities and remeasured at fair value during every reporting period, with gains or losses flowing through earnings.

Instead, Canopy classified them as equity for two straight fiscal years. That means the company’s balance sheet presentation was wrong, and fair value adjustments that should have hit the income statement never showed up properly. The company says the corrections are entirely non-cash and won’t affect revenue, gross margins, EBITDA, liquidity, or cash flow. Operationally, the business remains the same. But accounting professionals know this isn’t just bookkeeping trivia. Classification errors tied to complex financial instruments are exactly the kind of issues regulators, auditors, and investors obsess over because they raise questions about internal review controls and technical accounting oversight.

Friday Night News Dump?

Canopy announced the issue after markets closed, a timing choice that definitely raised eyebrows across the finance world. The company simultaneously disclosed that it would:

• Restate fiscal 2024 and fiscal 2025 financial statements
• Release FY2026 results on June 15, 2026
• File revised statements for prior years alongside the new results
• Apply for a Management Cease Trade Order (MCTO)

That last point matters more than many headlines acknowledged. An MCTO temporarily prevents directors and officers from trading company securities while the market operates with incomplete information. In other words, regulators want to ensure insiders don’t trade while corrected financial statements are still pending.

That’s not corporate theater. That’s governance in action. And investors clearly took the disclosure seriously. Markets may intellectually understand the phrase “non-cash adjustment,” but emotionally? A two-year restatement still feels like a flashing warning sign. On Bay Street and Wall Street alike, the phrase “restated financials” tends to spook people before they even reach page two of the filing.

How Did This Slip Through Two Audit Cycles?

The accounting guidance itself isn’t particularly obscure. IFRS rules around foreign-currency-denominated warrants have existed for years and are relatively well established. Still, these issues happen more often than many people realize, especially in industries with fast-moving capital structures like cannabis, biotech, and early-stage tech. A few factors likely contributed:

Complex Capital Structures Can Become a Hot Mess

Cannabis companies spent years raising capital aggressively through warrants, convertibles, and hybrid securities during the sector’s expansion boom. The sheer volume of financing activity created layers of accounting complexity that many finance teams struggled to manage in real time. When companies issue multiple instruments across currencies, jurisdictions, and reporting periods, classification risks multiply fast.

Foreign Currency Accounting Gets Underestimated

Cross-border financing structures often look simple at issuance but become technically messy under IFRS and GAAP analysis. Teams sometimes focus heavily on valuation mechanics while underestimating how currency denomination changes classification treatment. That’s where the “fixed-for-fixed” test becomes critical.

Prior-Year Accounting Treatments Become Sticky

This might be the biggest lesson of all. Once an accounting treatment gets approved in Year One, it often rolls forward automatically unless somebody actively re-challenges the conclusion. Teams assume the previous review was correct. Auditors may focus on new risks instead of reopening old determinations. Then suddenly, during a later review cycle, someone asks the uncomfortable question nobody asked earlier. And boom, here comes a restatement.

The Cannabis Industry Really Didn’t Need This

The broader cannabis industry has spent years trying to rebuild financial credibility after an era filled with impairments, restructuring charges, inflated growth projections, and aggressive expansion bets that aged like spoiled milk. Canopy’s error doesn’t involve fraud. There’s no indication of operational manipulation or missing cash. That distinction matters. But perception matters too. Institutional investors already approach cannabis reporting with skepticism because many companies in the sector have historically struggled with profitability, consistent controls, and stable reporting frameworks. A two-year accounting restatement at one of the industry’s most recognizable names becomes another reputational pothole for the sector. And the timing adds extra pressure.

On June 15, investors will effectively be reviewing:

• FY2026 earnings
• Restated FY2025 numbers
• Restated FY2024 numbers
• Updated disclosures
• Fair value adjustments
• Potentially revised audit commentary

That’s a lot for analysts to digest in one sitting. You can bet the farm analysts will be combing through every line item looking for broader control weaknesses or disclosure revisions.

The Real Lesson for Finance Professionals

• FX-denominated warrants require immediate accounting classification review at issuance.
• Liability vs. equity treatment under IAS 32 and IFRS 9 should never be assumed.
• “Non-cash” accounting errors can still damage investor confidence and stock prices.
• Prior-period accounting treatments should be re-evaluated regularly, not rolled forward blindly.
• Audit committees must challenge legacy accounting assumptions during every reporting cycle.
• Complex financial instruments need stronger documentation, technical review, and internal controls.
• Management cease-trade orders highlight the seriousness of incomplete financial disclosures.
• Transparent disclosure and quick corrective action are critical for maintaining market credibility.

So, What Happens Next?

Canopy’s accounting error shows that even non-cash mistakes can shake investor confidence fast. The case highlights why finance teams must carefully review complex instruments, regularly reassess prior accounting treatments, and maintain strong internal controls before small technical issues turn into public restatements.